Bionano Genomics (NASDAQ:BNGO) Stock Rating Lowered by LADENBURG THALM/SH SH

Bionano Genomics (NASDAQ:BNGO) was downgraded by equities research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a research report issued on Friday, Marketbeat reports.

Other analysts also recently issued research reports about the stock. Scotiabank reiterated a “sector perform” rating and issued a $1.00 target price (down previously from $6.00) on shares of Bionano Genomics in a report on Wednesday, August 28th. BTIG Research downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 10th.

Bionano Genomics Price Performance

Bionano Genomics stock opened at $0.26 on Friday. The stock has a market capitalization of $22.01 million, a price-to-earnings ratio of -0.05 and a beta of 2.37. Bionano Genomics has a 52-week low of $0.24 and a 52-week high of $2.27. The stock’s 50 day moving average price is $0.37 and its two-hundred day moving average price is $0.60. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.11 and a current ratio of 1.63.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new stake in shares of Bionano Genomics in the 2nd quarter worth approximately $1,138,000. Cetera Advisors LLC bought a new stake in Bionano Genomics in the first quarter worth $163,000. GSA Capital Partners LLP bought a new stake in Bionano Genomics in the third quarter worth $46,000. Carret Asset Management LLC boosted its position in Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after buying an additional 40,055 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Bionano Genomics by 123.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock valued at $79,000 after buying an additional 38,900 shares during the last quarter. Institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.